

Ming-Zhi Zhang

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7628698/ming-zhi-zhang-publications-by-citations.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

207 papers	2,382 citations	23 h-index	39 g-index
228 ext. papers	3,204 ext. citations	4.7 avg, IF	5.3 L-index

#	Paper	IF	Citations
207	PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?. <i>Frontiers in Immunology</i> , 2017 , 8, 1597	8.4	145
206	Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor. <i>Journal of Hematology and Oncology</i> , 2016 , 9, 21	22.4	140
205	Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia. <i>Journal of Hematology and Oncology</i> , 2015 , 8, 104	22.4	95
204	Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma. <i>Journal of Hematology and Oncology</i> , 2018 , 11, 15	22.4	93
203	DDGP versus SMILE in Newly Diagnosed Advanced Natural Killer/T-Cell Lymphoma: A Randomized Controlled, Multicenter, Open-label Study in China. <i>Clinical Cancer Research</i> , 2016 , 22, 5223-5228	12.9	72
202	miR-21 depletion in macrophages promotes tumoricidal polarization and enhances PD-1 immunotherapy. <i>Oncogene</i> , 2018 , 37, 3151-3165	9.2	64
201	AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy. <i>Journal of Hematology and Oncology</i> , 2015 , 8, 96	22.4	62
200	miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy. <i>Journal of Hematology and Oncology</i> , 2018 , 11, 58	22.4	55
199	L265P Mutation in Lymphoid Malignancies. <i>Cancer Research</i> , 2018 , 78, 2457-2462	10.1	52
198	Dual TGF- β and PD-1 blockade synergistically enhances MAGE-A3-specific CD8 T cell response in esophageal squamous cell carcinoma. <i>International Journal of Cancer</i> , 2018 , 143, 2561-2574	7.5	49
197	Long Noncoding RNA PlncRNA-1 Promotes Colorectal Cancer Cell Progression by Regulating the PI3K/Akt Signaling Pathway. <i>Oncology Research</i> , 2018 , 26, 261-268	4.8	39
196	Application of mitochondrial pyruvate carrier blocker UK5099 creates metabolic reprogram and greater stem-like properties in LnCap prostate cancer cells in vitro. <i>Oncotarget</i> , 2015 , 6, 37758-69	3.3	38
195	Mitochondrial pyruvate carrier function determines cell stemness and metabolic reprogramming in cancer cells. <i>Oncotarget</i> , 2017 , 8, 46363-46380	3.3	37
194	Role of programmed death ligands in effective T-cell interactions in extranodal natural killer/T-cell lymphoma. <i>Oncology Letters</i> , 2014 , 8, 1461-1469	2.6	36
193	miR-455-3p serves as prognostic factor and regulates the proliferation and migration of non-small cell lung cancer through targeting HOXB5. <i>Biochemical and Biophysical Research Communications</i> , 2018 , 495, 1074-1080	3.4	34
192	TAZ promotes temozolomide resistance by upregulating MCL-1 in human glioma cells. <i>Biochemical and Biophysical Research Communications</i> , 2015 , 463, 638-43	3.4	33
191	Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2015 , 6, 23157-80	3.3	32

190	Mitochondrial pyruvate carrier function is negatively linked to Warburg phenotype in vitro and malignant features in esophageal squamous cell carcinomas. <i>Oncotarget</i> , 2017 , 8, 1058-1073	3.3	31
189	Discovery and validation of the tumor-suppressive function of long noncoding RNA PANDA in human diffuse large B-cell lymphoma through the inactivation of MAPK/ERK signaling pathway. <i>Oncotarget</i> , 2017 , 8, 72182-72196	3.3	31
188	c-Myc mediated upregulation of long noncoding RNA SNHG12 regulates proliferation and drug sensitivity in natural killer/T-cell lymphoma. <i>Journal of Cellular Biochemistry</i> , 2019 , 120, 12628-12637	4.7	26
187	MPC1 and MPC2 expressions are associated with favorable clinical outcomes in prostate cancer. <i>BMC Cancer</i> , 2016 , 16, 894	4.8	24
186	Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside. <i>Oncotarget</i> , 2017 , 8, 7201-7207	3.3	23
185	MiRNA-155 regulates lymphangiogenesis in natural killer/T-cell lymphoma by targeting BRG1. <i>Cancer Biology and Therapy</i> , 2019 , 20, 31-41	4.6	23
184	Recurrent PDGFRB mutations in unicentric Castleman disease. <i>Leukemia</i> , 2019 , 33, 1035-1038	10.7	21
183	The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T-cell lymphoma with analysis of biomarkers. <i>British Journal of Haematology</i> , 2017 , 178, 772-780	4.5	20
182	PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program. <i>Modern Pathology</i> , 2019 , 32, 741-754	9.8	20
181	RelA NF- κ B subunit activation as a therapeutic target in diffuse large B-cell lymphoma. <i>Aging</i> , 2016 , 8, 3321-3340	5.6	20
180	Circular METRN RNA hsa_circ_0037251 Promotes Glioma Progression by Sponging miR-1229-3p and Regulating mTOR Expression. <i>Scientific Reports</i> , 2019 , 9, 19791	4.9	20
179	Activated hippo signal pathway inhibits cell proliferation and promotes apoptosis in NK/T cell lymphoma cells. <i>Cancer Medicine</i> , 2019 , 8, 3892-3904	4.8	17
178	Recurrent mutations in epigenetic modifiers and the PI3K/AKT/mTOR pathway in subcutaneous panniculitis-like T-cell lymphoma. <i>British Journal of Haematology</i> , 2018 , 181, 406-410	4.5	17
177	Inhibition of RANKL-induced osteoclastogenesis through the suppression of the ERK signaling pathway by astragaloside IV and attenuation of titanium-particle-induced osteolysis. <i>International Journal of Molecular Medicine</i> , 2015 , 36, 1335-44	4.4	17
176	MicroRNA-155 is a potential molecular marker of natural killer/T-cell lymphoma. <i>Oncotarget</i> , 2016 , 7, 53808-53819	3.3	17
175	Evaluation of AKT phosphorylation and PTEN loss and their correlation with the resistance of rituximab in DLBCL. <i>International Journal of Clinical and Experimental Pathology</i> , 2015 , 8, 14875-84	1.4	17
174	Targeting PD-L1 in non-small cell lung cancer using CAR T cells. <i>Oncogenesis</i> , 2020 , 9, 72	6.6	17
173	Utility of baseline, interim and end-of-treatment F-FDG PET/CT in extranodal natural killer/T-cell lymphoma patients treated with L-asparaginase/pegaspargase. <i>Scientific Reports</i> , 2017 , 7, 41057	4.9	16

172	Leucovorin Enhances the Anti-cancer Effect of Bortezomib in Colorectal Cancer Cells. <i>Scientific Reports</i> , 2017 , 7, 682	4.9	16
171	Recurrent GNAQ mutation encoding T96S in natural killer/T cell lymphoma. <i>Nature Communications</i> , 2019 , 10, 4209	17.4	16
170	Complete Blood Count Score Model Integrating Reduced Lymphocyte-Monocyte Ratio, Elevated Neutrophil-Lymphocyte Ratio, and Elevated Platelet-Lymphocyte Ratio Predicts Inferior Clinical Outcomes in Adult T-Lymphoblastic Lymphoma. <i>Oncologist</i> , 2019 , 24, e1123-e1131	5.7	16
169	Anti-PD1 up-regulates PD-L1 expression and inhibits T-cell lymphoma progression: possible involvement of an IFN- γ -associated JAK-STAT pathway. <i>OncoTargets and Therapy</i> , 2019 , 12, 2079-2088	4.4	16
168	Pyruvate dehydrogenase expression is negatively associated with cell stemness and worse clinical outcome in prostate cancers. <i>Oncotarget</i> , 2017 , 8, 13344-13356	3.3	16
167	ILs-3, 6 and 11 increase, but ILs-10 and 24 decrease stemness of human prostate cancer cells in vitro. <i>Oncotarget</i> , 2015 , 6, 42687-703	3.3	16
166	CircCDYL Serves as a New Biomarker in Mantle Cell Lymphoma and Promotes Cell Proliferation. <i>Cancer Management and Research</i> , 2019 , 11, 10215-10221	3.6	16
165	Lymphoma associated hemophagocytic syndrome: A single-center retrospective study. <i>Oncology Letters</i> , 2018 , 16, 1275-1284	2.6	15
164	Inhibition of cell proliferation and metastasis of human hepatocellular carcinoma by miR-137 is regulated by CDC42. <i>Oncology Reports</i> , 2015 , 34, 2523-32	3.5	15
163	Efficacy and safety of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) regimen in newly diagnosed, advanced-stage extranodal natural killer/T-cell lymphoma: interim analysis of a phase 4 study NCT01501149. <i>Oncotarget</i> , 2016 , 7, 55721-55731	3.3	15
162	Establishment of mitochondrial pyruvate carrier 1 (MPC1) gene knockout mice with preliminary gene function analyses. <i>Oncotarget</i> , 2016 , 7, 79981-79994	3.3	15
161	Targeting Six1 by lentivirus-mediated RNA interference inhibits colorectal cancer cell growth and invasion. <i>International Journal of Clinical and Experimental Pathology</i> , 2014 , 7, 631-9	1.4	15
160	PDHA1 gene knockout in prostate cancer cells results in metabolic reprogramming towards greater glutamine dependence. <i>Oncotarget</i> , 2016 , 7, 53837-53852	3.3	15
159	A proposal for a new staging system for extranodal natural killer T-cell lymphoma: a multicenter study from China and Asia Lymphoma Study Group. <i>Leukemia</i> , 2020 , 34, 2243-2248	10.7	14
158	S100A9 and ORM1 serve as predictors of therapeutic response and prognostic factors in advanced extranodal NK/T cell lymphoma patients treated with pegaspargase/gemcitabine. <i>Scientific Reports</i> , 2016 , 6, 23695	4.9	14
157	TIPE2 suppresses progression and tumorigenesis of esophageal carcinoma via inhibition of the Wnt/ β -catenin pathway. <i>Journal of Translational Medicine</i> , 2018 , 16, 7	8.5	14
156	miRNA-155 modulates the malignant biological characteristics of NK/T-cell lymphoma cells by targeting FOXO3a gene. <i>Journal of Huazhong University of Science and Technology [Medical Sciences]</i> , 2014 , 34, 882-888		14
155	AEG-1 is involved in hypoxia-induced autophagy and decreases chemosensitivity in T-cell lymphoma. <i>Molecular Medicine</i> , 2018 , 24, 35	6.2	14

154	ATP-binding cassette sub-family C member 4 (ABCC4) is overexpressed in human NK/T-cell lymphoma and regulates chemotherapy sensitivity: Potential as a functional therapeutic target. <i>Leukemia Research</i> , 2015 , 39, 1448-54	2.7	13
153	SPARC is down-regulated by DNA methylation and functions as a tumor suppressor in T-cell lymphoma. <i>Experimental Cell Research</i> , 2018 , 364, 125-132	4.2	13
152	High level of lncRNA H19 expression is associated with shorter survival in esophageal squamous cell cancer patients. <i>Pathology Research and Practice</i> , 2019 , 215, 152638	3.4	12
151	Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy. <i>Immunotherapy</i> , 2019 , 11, 515-529	3.8	12
150	XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53. <i>Journal of Hematology and Oncology</i> , 2020 , 13, 148	22.4	12
149	Fotemustine, teniposide and dexamethasone versus high-dose methotrexate plus cytarabine in newly diagnosed primary CNS lymphoma: a randomised phase 2 trial. <i>Journal of Neuro-Oncology</i> , 2018 , 140, 427-434	4.8	12
148	Non-coding RNAs in Natural Killer/T-Cell Lymphoma. <i>Frontiers in Oncology</i> , 2019 , 9, 515	5.3	12
147	Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II Study. <i>Blood</i> , 2019 , 134, 755-755	2.2	12
146	Generation of TALEN-mediated FH knockout rat model. <i>Oncotarget</i> , 2016 , 7, 61656-61669	3.3	12
145	The DDGP (cisplatin, dexamethasone, gemcitabine, and pegaspargase) regimen for treatment of extranodal natural killer (NK)/T-cell lymphoma, nasal type. <i>Oncotarget</i> , 2016 , 7, 58396-58404	3.3	12
144	Use of CAR-T cell therapy, PD-1 blockade, and their combination for the treatment of hematological malignancies. <i>Clinical Immunology</i> , 2020 , 214, 108382	9	11
143	Asparagine synthetase expression and its potential prognostic value in patients with NK/T cell lymphoma. <i>Oncology Reports</i> , 2014 , 32, 853-9	3.5	11
142	The effects and mechanism of action of <i>Prunella vulgaris</i> l extract on Jurkat human T lymphoma cell proliferation. <i>Chinese-German Journal of Clinical Oncology</i> , 2009 , 8, 426-429		11
141	ADAM10 mediates the cell invasion and metastasis of human esophageal squamous cell carcinoma via regulation of E-cadherin activity. <i>Oncology Reports</i> , 2016 , 35, 2785-94	3.5	11
140	Co-delivery of paclitaxel and gemcitabine by methoxy poly(ethylene glycol)-poly(lactide-coglycolide)-polypeptide nanoparticles for effective breast cancer therapy. <i>Anti-Cancer Drugs</i> , 2018 , 29, 637-645	2.4	11
139	Expression and clinical significance of cyclooxygenase-2 and interleukin-32 in primary gastric B-cell lymphoma. <i>Oncology Letters</i> , 2016 , 11, 693-698	2.6	10
138	Six1 promotes glioblastoma cell proliferation and invasion by upregulation of connective tissue growth factor. <i>American Journal of Cancer Research</i> , 2015 , 5, 1823-30	4.4	10
137	Effects of microRNA-21 on the biological functions of T-cell acute lymphoblastic lymphoma/leukemia. <i>Oncology Letters</i> , 2016 , 12, 4173-4180	2.6	10

136	Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplorer-002). <i>Journal of Hematology and Oncology</i> , 2021 , 14, 12	22.4	10
135	Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed/refractory large B-cell lymphoma in China. <i>Cancer Medicine</i> , 2021 , 10, 999-1011	4.8	10
134	Decreased Expression of PDHE1 Predicts Worse Clinical Outcome in Esophageal Squamous Cell Carcinoma. <i>Anticancer Research</i> , 2015 , 35, 5533-8	2.3	10
133	Prognostic significance of CD30 expression in nasal natural killer/T-cell lymphoma. <i>Oncology Letters</i> , 2017 , 13, 1211-1215	2.6	9
132	Clinical efficacy of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) in the initial treatment of advanced stage (stage III-IV) extranodal NK/T-cell lymphoma, and its correlation with Epstein-Barr virus. <i>Cancer Management and Research</i> , 2019 , 11, 3555-3564	3.6	9
131	Effect of Concomitant Positive Hepatitis B Surface Antigen on the Risk of Liver Metastasis: A Retrospective Clinical Study of 4033 Consecutive Cases of Newly Diagnosed Colorectal Cancer. <i>Clinical Infectious Diseases</i> , 2018 , 66, 1948-1952	11.6	9
130	Tissue-specific microRNA expression alters cancer susceptibility conferred by a TP53 noncoding variant. <i>Nature Communications</i> , 2019 , 10, 5061	17.4	9
129	A neutralized human LMP1-IgG inhibits ENKTL growth by suppressing the JAK3/STAT3 signaling pathway. <i>Oncotarget</i> , 2017 , 8, 10954-10965	3.3	9
128	Feedback activation of NF-KB signaling leads to adaptive resistance to EZH2 inhibitors in prostate cancer cells. <i>Cancer Cell International</i> , 2021 , 21, 191	6.4	9
127	Patients over 40 years old with precursor T-cell lymphoblastic lymphoma have different prognostic factors comparing to the youngsters. <i>Scientific Reports</i> , 2018 , 8, 1088	4.9	8
126	Effect of rituximab on primary central nervous system lymphoma: a meta-analysis. <i>International Journal of Hematology</i> , 2017 , 106, 612-621	2.3	8
125	Pretreatment 14-3-3 epsilon level is predictive for advanced extranodal NK/T cell lymphoma therapeutic response to asparaginase-based chemotherapy. <i>Proteomics - Clinical Applications</i> , 2017 , 11, 1600111	3.1	8
124	Peroxisredoxin 1 is involved in disassembly of flagella and cilia. <i>Biochemical and Biophysical Research Communications</i> , 2014 , 444, 420-6	3.4	8
123	Role of circular RNA in hematological malignancies. <i>Oncology Letters</i> , 2019 , 18, 4385-4392	2.6	8
122	miR-150 might inhibit cell proliferation and promote cell apoptosis by targeting LMO4 in Burkitt lymphoma. <i>Journal of Cellular Physiology</i> , 2019 , 234, 9652-9662	7	8
121	FOXC1 silencing inhibits the epithelial-to-mesenchymal transition of glioma cells: Involvement of Eatenin signaling. <i>Molecular Medicine Reports</i> , 2019 , 19, 251-261	2.9	8
120	Bushenshugan Formula Attenuates the Development of Lung Cancer by Inhibiting Epithelial-Mesenchymal Transition. <i>Cellular Physiology and Biochemistry</i> , 2018 , 47, 1977-1988	3.9	8
119	Soluble fms-like tyrosine kinase-1-enriched exosomes suppress the growth of small cell lung cancer by inhibiting endothelial cell migration. <i>Thoracic Cancer</i> , 2019 , 10, 1962-1972	3.2	7

118	Safety and efficacy of low-dose pre-phase before conventional-dose chemotherapy for ulcerative gastric diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015 , 56, 2613-8	1.9	7
117	Efficacy and Survival in Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Randomized, Controlled, Multicenter and Open-Labelled Study with Ddgp Regimen Versus SMILE Regimen. <i>Blood</i> , 2019 , 134, 463-463	2.2	7
116	First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3026-3026	2.2	7
115	Effective Treatment with PD-1 Antibody, Chidamide, Etoposide, and Thalidomide (PCET) for Relapsed/Refractory Natural Killer/T-Cell Lymphoma: A Report of Three Cases. <i>OncoTargets and Therapy</i> , 2020 , 13, 7189-7197	4.4	7
114	A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma. <i>Journal of Hematology and Oncology</i> , 2020 , 13, 38	22.4	7
113	High-Grade B-Cell Lymphomas, Not Otherwise Specified: A Study of 41 Cases. <i>Cancer Management and Research</i> , 2020 , 12, 1903-1912	3.6	7
112	MIR-199a mediated the dissemination of human mantle cell lymphoma by interacting with the CCR7/CCL21 pair. <i>Anti-Cancer Drugs</i> , 2018 , 29, 861-870	2.4	7
111	Platelet-derived growth factor receptor alpha (PDGFR α) is overexpressed in NK/T-cell lymphoma and mediates cell survival. <i>Biochemical and Biophysical Research Communications</i> , 2018 , 504, 525-531	3.4	7
110	Advances in the treatment and prognosis of anaplastic lymphoma kinase negative anaplastic large cell lymphoma. <i>Hematology</i> , 2019 , 24, 440-445	2.2	6
109	Efficacy of dose-adjusted EPOCH plus rituximab/R-CHOP regimens and the prognosis analysis in patients with , gene copy number gain lymphoma and double-hit lymphoma: results from a single institution retrospective clinical study. <i>Cancer Management and Research</i> , 2019 , 11, 1363-1372	3.6	6
108	The clinical features and prognosis of 100 AIDS-related lymphoma cases. <i>Scientific Reports</i> , 2019 , 9, 5381	4.9	6
107	High SRPX2 protein expression predicts unfavorable clinical outcome in patients with prostate cancer. <i>OncoTargets and Therapy</i> , 2018 , 11, 3149-3157	4.4	6
106	An open label, single-armed, exploratory study of apatinib (a novel VEGFR-2 tyrosine kinase inhibitor) in patients with relapsed or refractory non-Hodgkin lymphoma. <i>Oncotarget</i> , 2018 , 9, 16213-16219	3.3	6
105	Cancer stem cells as a potential therapeutic target in breast cancer. <i>Stem Cell Investigation</i> , 2014 , 1, 14	5.1	6
104	Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma. <i>Clinical Epigenetics</i> , 2020 , 12, 169	7.7	6
103	Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: a prospective, multicentre, non-interventional study. <i>BMC Cancer</i> , 2016 , 16, 537	4.8	6
102	Aldehyde Dehydrogenase-1 Expression Predicts Unfavorable Outcomes in Patients with Esophageal Squamous Cell Carcinoma. <i>Anticancer Research</i> , 2016 , 36, 343-9	2.3	6
101	Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study. <i>Drug Design, Development and Therapy</i> , 2020 , 14, 275-284	4.4	5

100	Therapy-related acute myeloid leukemia in patients with lymphoma: A report of four cases and review of the literature. <i>Oncology Letters</i> , 2015 , 10, 3261-3265	2.6	5
99	Potential strategies against resistance to CAR T-cell therapy in haematological malignancies. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920962963	5.4	5
98	Baseline Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured on 18F-FDG PET-CT Predict Outcomes in T-Cell Lymphoblastic Lymphoma. <i>Cancer Research and Treatment</i> , 2021 , 53, 837-846	5.2	5
97	MYD88 L265P elicits mutation-specific ubiquitination to drive NF- κ B activation and lymphomagenesis. <i>Blood</i> , 2021 , 137, 1615-1627	2.2	5
96	Identification of low-dose radiation-induced exosomal circ-METRN and miR-4709-3p/GRB14/PDGFR β pathway as a key regulatory mechanism in Glioblastoma progression and radioresistance: Functional validation and clinical theranostic significance. <i>International Journal of Biological Sciences</i> , 2021 , 17, 1061-1078	11.2	5
95	B2 microglobulin is a novel prognostic marker of Angioimmunoblastic T-cell lymphoma. <i>Scientific Reports</i> , 2018 , 8, 12907	4.9	5
94	Causes of mortality in cases with extra nodal natural killer/T-cell lymphoma, nasal type: A cohort study. <i>PLoS ONE</i> , 2019 , 14, e0214860	3.7	4
93	CDC27 Promotes Tumor Progression and Affects PD-L1 Expression in T-Cell Lymphoblastic Lymphoma. <i>Frontiers in Oncology</i> , 2020 , 10, 488	5.3	4
92	Genomic and outcome analysis of adult T-cell lymphoblastic lymphoma. <i>Haematologica</i> , 2020 , 105, e107-6110	4.10	4
91	Long-Term Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II Study. <i>Blood</i> , 2020 , 136, 1-1	2.2	4
90	B7-CD28 gene family expression is associated with prognostic and immunological characteristics of diffuse large B-cell lymphoma. <i>Aging</i> , 2019 , 11, 3939-3957	5.6	4
89	Selection of new immunotherapy targets for NK/T cell lymphoma. <i>American Journal of Translational Research (discontinued)</i> , 2020 , 12, 7034-7047	3	4
88	A Single-Arm, Open-Label, Pilot Trial of Autologous CD7-CAR-T Cells for CD7 Positive Relapsed and Refractory T-Lymphoblastic Leukemia/Lymphoma. <i>Blood</i> , 2021 , 138, 3829-3829	2.2	4
87	A Phase I clinical trial of chimeric antigen receptor-modified T cells in patients with relapsed and refractory lymphoma. <i>Immunotherapy</i> , 2020 , 12, 681-696	3.8	4
86	Research on the midterm efficacy and prognosis of patients with diffuse large B-cell lymphoma by different evaluation methods in interim PET/CT. <i>European Journal of Radiology</i> , 2020 , 133, 109301	4.7	4
85	Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia. <i>Neoplasia</i> , 2021 , 23, 361-374	6.4	4
84	LncRNA MEG3 regulates breast cancer proliferation and apoptosis through miR-141-3p/RBMS3 axis. <i>Genomics</i> , 2021 , 113, 1689-1704	4.3	4
83	Efficacy and safety of GLS-010 (zimberelimab) in patients with relapsed or refractory classical Hodgkin lymphoma: A multicenter, single-arm, phase II study. <i>European Journal of Cancer</i> , 2021 ,	7.5	4

82	Prognostic analysis of CD5 expression in double-hit diffuse large B-cell lymphoma and effectiveness comparison in patients treated with dose-adjusted EPOCH plus rituximab/R-CHOP regimens. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2019 , 9, 33-43	2.6	3
81	Apatinib, a novel VEGFR-2 tyrosine kinase inhibitor, for relapsed and refractory nasopharyngeal carcinoma: data from an open-label, single-arm, exploratory study. <i>Investigational New Drugs</i> , 2020 , 38, 1847-1853	4.3	3
80	Outcomes of GDPT (gemcitabine, cisplatin, prednisone, thalidomide) CHOP in newly diagnosed peripheral T-cell lymphoma patients. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920923829	5.4	3
79	Humoral immunoreaction induced by TCR DNA vaccine for beta chain of T cell lymphoma. <i>Vaccine</i> , 2004 , 22, 2031-41	4.1	3
78	Clinical features and treatment outcomes of primary ocular adnexal mucosa-associated lymphoid tissue lymphoma: a single center retrospective analysis of 64 patients in China. <i>International Journal of Ophthalmology</i> , 2019 , 12, 1731-1736	1.4	3
77	Anti-senescence role of heterozygous fumarate hydratase gene knockout in rat lung fibroblasts. <i>Aging</i> , 2019 , 11, 573-589	5.6	3
76	Decreased expression of pyruvate dehydrogenase A1 predicts an unfavorable prognosis in ovarian carcinoma. <i>American Journal of Cancer Research</i> , 2016 , 6, 2076-2087	4.4	3
75	Long-term remission of subcutaneous panniculitis-like T-cell lymphoma with central nervous system involvement: A case report. <i>Oncology Letters</i> , 2016 , 12, 611-614	2.6	3
74	One method to establish Epstein-Barr virus-associated NK/T cell lymphoma mouse models. <i>Journal of Cellular and Molecular Medicine</i> , 2019 , 23, 1509-1516	5.6	3
73	Radiotherapy vs sequential pegaspargase, gemcitabine, cisplatin and dexamethasone and radiotherapy in newly diagnosed early natural killer/T-cell lymphoma: A randomized, controlled, open-label, multicenter study. <i>International Journal of Cancer</i> , 2021 , 148, 1470-1477	7.5	3
72	Analyses and treatment of simultaneous bi-lineage malignancies of myeloid leukemia and lymphoma: Two case reports and a literature review. <i>Oncology Letters</i> , 2018 , 16, 6624-6632	2.6	3
71	Conserved cell populations in doxorubicin-resistant human nasal natural killer/T cell lymphoma cell line: super multidrug resistant cells?. <i>Cancer Cell International</i> , 2018 , 18, 150	6.4	3
70	Suppression of latent transforming growth factor- β binding protein 1 (LTBP1) inhibits natural killer/ T cell lymphoma progression by inactivating the TGF- β /Smad and p38 pathways. <i>Experimental Cell Research</i> , 2021 , 407, 112790	4.2	3
69	Prognostic nomogram for overall survival in upper aerodigestive tract extranodal natural killer/T-cell lymphoma, nasal type, stages IE and IIE: A SEER-based study. <i>Oncology Letters</i> , 2019 , 18, 3493-3500	3.6	2
68	Analysis of clinical characteristics and prognosis factors of 71 cases with HIV-negative Castleman's disease: hypoproteinemia is an unfavorable prognostic factor which should be treated appropriately. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018 , 144, 1265-1277	4.9	2
67	Generation of an oxoglutarate dehydrogenase knockout rat model and the effect of a high-fat diet.. <i>RSC Advances</i> , 2018 , 8, 16636-16644	3.7	2
66	IL-13 and IL-13R α are overexpressed in extranodal natural killer/T cell lymphoma and mediate tumor cell proliferation. <i>Biochemical and Biophysical Research Communications</i> , 2018 , 503, 2715-2720	3.4	2
65	Natural killer/T-cell lymphoma-associated hemophagocytic syndrome: A case report. <i>Oncology Letters</i> , 2014 , 8, 886-890	2.6	2

64	Gelsolin regulates proliferation, apoptosis and invasion in natural killer/T-cell lymphoma cells. <i>Biology Open</i> , 2018 , 7, 1-10. 2.2 2
63	A retrospective study of external beam radiation, neutron brachytherapy, and concurrent chemotherapy for patients with localized advanced carcinoma of the esophagus. <i>Radiation Oncology</i> , 2014 , 9, 294 4.2 2
62	Pooled Analysis of Safety Data from Clinical Trials of Orelabrutinib Monotherapy in Hematologic Malignancies. <i>Blood</i> , 2020 , 136, 43-43 2.2 2
61	GLS-010, a novel anti-PD-1 mAb in Chinese patients with relapsed or refractory classical Hodgkin lymphoma: Preliminary result of a phase II clinical trial.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e14072-e14072 2.3 2
60	ORP8 induces apoptosis by releasing cytochrome c from mitochondria in non-small cell lung cancer. <i>Oncology Reports</i> , 2020 , 43, 1516-1524 3.5 2
59	Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma. <i>Annals of Hematology</i> , 2021 , 100, 1509-1516 3 2
58	Overexpression of S100A9 in tumor stroma contribute to immune evasion of NK/T cell lymphoma and predict poor response rate. <i>Scientific Reports</i> , 2021 , 11, 11220 4.9 2
57	Bendamustine treatment of Chinese patients with relapsed indolent non-Hodgkin lymphoma: a multicenter, open-label, single-arm, phase 3 study. <i>Chinese Medical Journal</i> , 2021 , 134, 1299-1309 2.9 2
56	Combination of Decitabine and a Modified Regimen of Cisplatin, Cytarabine and Dexamethasone: A Potential Salvage Regimen for Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Treatment Failure. <i>Frontiers in Oncology</i> , 2021 , 11, 687374 5.3 2
55	Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China: A Prospective, Multicenter, Noninterventional Study. <i>Chinese Medical Journal</i> , 2018 , 133, 1767-1775 2.9 2
54	IL-13 Contributes to Drug Resistance of NK/T-Cell Lymphoma Cells by Regulating ABCC4. <i>BioMed Research International</i> , 2018 , 2018, 2606834 3 2
53	GPNMB promotes the progression of diffuse large B cell lymphoma via YAP1-mediated activation of the Wnt/ β -catenin signaling pathway. <i>Archives of Biochemistry and Biophysics</i> , 2021 , 710, 108998 4.1 2
52	IL-10 contributes to gemcitabine resistance in extranodal NK/T-cell lymphoma cells via ABCC4.. <i>Investigational New Drugs</i> , 2022 , 1 4.3 2
51	Penile metastasis secondary to nasal-type extranodal natural killer/T-cell lymphoma: A case report and review of the literature. <i>Oncology Letters</i> , 2018 , 15, 8034-8038 2.6 1
50	Orelabrutinib-bruton tyrosine kinase inhibitor-based regimens in the treatment of central nervous system lymphoma: a retrospective study.. <i>Investigational New Drugs</i> , 2022 , 1 4.3 1
49	Decitabine Can Improve the Efficacy of Second-Line Chemotherapy in Relapsed or Refractory Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2019 , 134, 5221-5221 2.2 1
48	CircADARB1 serves as a new biomarker in natural killer T-cell lymphoma and a potential regulator of p-Stat3. <i>Cancer Cell International</i> , 2021 , 21, 594 6.4 1
47	The Impact of the Immunophenotyping Characteristics of Patients' Peripheral Blood on the Manufacturing and Clinical Outcome of CD7-Targeted Chimeric Antigen Receptor T Cells. <i>Blood</i> , 2021 , 138, 3830-3830 2.2 1

46	Anti-PD-1-Antibody (Tislelizumab) Combined with Deacetylase Inhibitor (Chidamide), Lenalidomide and Etoposide for the Treatment of Refractory/Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r-ENKTL): Preliminary Results from a Prospective, Multicenter, Single-Arm, Phase II Trial. <i>Blood</i> , 2021 , 138, 1368-1368	2.2	1
45	The Synergistic Anticancer Effect of a Combination of Chidamide and Etoposide Against NK/T Cell Lymphoma. <i>Blood</i> , 2021 , 138, 3987-3987	2.2	1
44	Primary Causes of Death in Patients with Non-Hodgkin's Lymphoma: A Retrospective Cohort Study. <i>Cancer Management and Research</i> , 2020 , 12, 3155-3162	3.6	1
43	Prognostic relevance of genetic variations in T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma.. <i>Translational Cancer Research</i> , 2019 , 8, 2485-2495	0.3	1
42	Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study.. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2022 , 38, 42-50	0.7	1
41	Identification of Prognostic Related Genes of Tumor Microenvironment Derived From Esophageal Cancer Patients. <i>Pathology and Oncology Research</i> , 2021 , 27, 589662	2.6	1
40	Hydroa vacciniforme-like lymphoproliferative disorder: A clinicopathological, immunohistochemical, and prognostic study of 24 cases in China. <i>Journal of Dermatology</i> , 2021 , 48, 1315-1326	1.6	1
39	Clinical analysis of patients with primary and secondary extranodal natural killer/T-cell lymphoma of central nervous system. <i>Hematological Oncology</i> , 2021 ,	1.3	1
38	Epigenetics in the Pathogenesis and Treatment of Cutaneous T-Cell Lymphoma. <i>Frontiers in Oncology</i> , 2021 , 11, 663961	5.3	1
37	DDGP vs. SMILE in Relapsed/Refractory Extranodal Natural Killer/T-cell Lymphoma, Nasal Type: A Retrospective Study of 54 Patients. <i>Clinical and Translational Science</i> , 2021 , 14, 405-411	4.9	1
36	Emerging Roles for the Gut Microbiome in Lymphoid Neoplasms. <i>Clinical Medicine Insights: Oncology</i> , 2021 , 15, 11795549211024197	1.8	1
35	Updating targets for natural killer/T-cell lymphoma immunotherapy. <i>Cancer Biology and Medicine</i> , 2021 , 18, 52-62	5.2	1
34	Clinicopathological analysis of the hydroa vacciniforme-like lymphoproliferative disorder with natural killer cell phenotype compared with cutaneous natural killer T-cell lymphoma. <i>Experimental and Therapeutic Medicine</i> , 2018 , 16, 4772-4778	2.1	1
33	Significant Diagnostic and Prognostic Value of FLAD1 and Related MicroRNAs in Breast Cancer after a Pan-Cancer Analysis. <i>Disease Markers</i> , 2021 , 2021, 6962526	3.2	1
32	Characteristics and Clinical Implications of the Nasal Microbiota in Extranodal NK/T-Cell Lymphoma, Nasal Type. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021 , 11, 686595	5.9	1
31	Positive PD-L1 expression is predictive for patients with advanced EGFR wild-type non-small cell lung cancer treated with gemcitabine and cisplatin. <i>Oncology Letters</i> , 2019 , 18, 161-168	2.6	0
30	Clinical Response of CD19 CAR-T Cells (relmacabtagene autoleucel, relma-cel) in Adults with Heavily-Pre-Treated Relapsed/Refractory (r/r) Large B-Cell Lymphoma in China. <i>Blood</i> , 2020 , 136, 39-40	2.2	0
29	A multicenter retrospective study on the real-world outcomes of autologous vs. allogeneic hematopoietic stem cell transplantation for peripheral T-cell lymphoma in China. <i>Chinese Medical Journal</i> , 2021 , 134, 1584-1592	2.9	0

28	New prognostic models for extranodal natural killer T-cell lymphoma, nasal-type using Cox regression and machine learning.. <i>Translational Cancer Research</i> , 2021 , 10, 613-626	0.3	o
27	Interleukin-6 reverses Adriamycin resistance in nasal NK/T-cell lymphoma via downregulation of ABCC4 and inactivation of the JAK2/STAT3/NF- κ B/P65 pathway. <i>Environmental Toxicology and Pharmacology</i> , 2021 , 85, 103639	5.8	o
26	CD5-positive marginal zone lymphoma: Clinicopathological features and survival outcomes.. <i>Leukemia Research</i> , 2022 , 117, 106840	2.7	o
25	Hsa_circ_0023984 Regulates Cell Proliferation, Migration, and Invasion in Esophageal Squamous Cancer via Regulating miR-1294/PI3K/Akt/c-Myc Pathway.. <i>Applied Biochemistry and Biotechnology</i> , 2022 , 1	3.2	o
24	Gemcitabine, cisplatin, prednisone, and thalidomide for relapse and refractory peripheral T-cell lymphoma: a retrospective study from China. <i>Cancer Management and Research</i> , 2019 , 11, 8277-8284	3.6	
23	Low Expression of 14-3-3beta Is Associated With Adverse Survival of Diffuse Large B-Cell Lymphoma Patients. <i>Frontiers in Medicine</i> , 2019 , 6, 237	4.9	
22	RING box protein-1 gene involved in flagellar disassembly of <i>Dunaliella salina</i> . <i>Folia Microbiologica</i> , 2017 , 62, 57-62	2.8	
21	Activating NOTCH1 Mutations Alter T-ALL Chemosensitivity By PREX2-AKT Pathway. <i>Blood</i> , 2020 , 136, 46-47	2.2	
20	Improving outcomes in limited-stage de novo CD5+ DLBCL: systemic approaches with consolidative radiation.. <i>Leukemia and Lymphoma</i> , 2022 , 1-6	1.9	
19	Efficacy and Safety of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody (SCT400) Combined with CHOP in Patients with Treatment-Naïve Diffuse Large B-Cell Lymphoma: A Multicenter, Randomized, Single-Blind, Parallel Active-Controlled, Phase III Study. <i>Blood</i> , 2021 , 138, 2480-2480	2.2	
18	Fotemustine-Containing Regimens Versus Regimens Based on High-Dose Methotrexate in Newly Diagnosed PCNSL. <i>Blood</i> , 2021 , 138, 4559-4559	2.2	
17	Analysis of the Tumor Microenvironment By Quantitative Immunohistochemistry Reveals Novel Predictors in Classic Hodgkin Lymphoma Treated with Anti-PD1 Therapy. <i>Blood</i> , 2021 , 138, 4530-4530	2.2	
16	Integrating Circulating Tumor DNA Features and Plasma Protein Markers to Detected Early Lymphoid Neoplasm. <i>Blood</i> , 2021 , 138, 4489-4489	2.2	
15	Short-Term effects of cinobufagin in the treatment of middle and advanced malignant tumors 1997 , 3, 120-122		
14	A proposal for a new staging system for extranodal natural killer T-cell lymphoma, nasal type, to predict the treatment strategy: A multicentre study from the Chinese Southwest Oncology Group and Asia Lymphoma Study Group.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 7552-7552	2.2	
13	Prognostic Value of Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured By 18F-FDG PET-CT in Patients with T-Cell Lymphoblastic Lymphoma. <i>Blood</i> , 2019 , 134, 2851-2851	2.2	
12	Efficacy and Safety of Apatinib in Relapsed or Refractory Diffuse Large B Cell Lymphoma: An Open-Label, Single-Arm, Prospective Study. <i>Blood</i> , 2019 , 134, 2873-2873	2.2	
11	Latent Membrane Protein 1 Contributes to Deficient Cellular Immunity in NKTCL Patients. <i>Blood</i> , 2019 , 134, 3969-3969	2.2	

- 10 Gls-010, a novel anti-PD-1 mAb in Chinese patients with relapsed or refractory classical Hodgkin lymphoma: Preliminary impressive result of a phase II clinical trial.. *Journal of Clinical Oncology*, **2020**, 38, 8033-8033 2.2
- 9 Outcomes of GDPT (gemcitabine, cisplatin, prednisone,thalidomide) versus CHOP in newly diagnosed peripheral T-cell lymphoma patients.. *Journal of Clinical Oncology*, **2020**, 38, 8018-8018 2.2
- 8 sATP-binding cassette subfamilyG member2 enhances the multidrug resistance properties of human nasal natural killer/T-cell lymphoma side population cells. *Oncology Reports*, **2020**, 44, 1467-1478^{3,5}
- 7 A Prospective, Observational Study on the Safety and Effectiveness of Rituximab Plus Chemotherapy As the First-Line Treatment of Diffuse Large B-Cell Lymphoma. *Blood*, **2014**, 124, 5475-5475^{2,3}
- 6 a Proposal for a New Staging System of Extranodal Natural Killer T-cell Lymphoma, Nasal-Type: a Multicenter Study of Chinese Southwest Oncology Group (CSWOG). *Blood*, **2014**, 124, 4444-4444 2.2
- 5 GDPT Versus CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma: A Prospective Randomized Controlled, Open-Label Study (No.NCT01664975). *Blood*, **2016**, 128, 2989-2989 2.2
- 4 Identification and Validation of a Prognostic Prediction Model in Diffuse Large B-Cell Lymphoma.. *Frontiers in Endocrinology*, **2022**, 13, 846357 5.7
- 3 The Effect of Chronic Rhinosinusitis on the Staging and Prognosis of Extranodal Natural Killer/T-Cell Lymphoma: A Single-Center Retrospective Analysis.. *Frontiers in Oncology*, **2022**, 12, 878559^{5,3}
- 2 Advances in CD30- and PD-1-targeted therapies for relapsed or refractory Hodgkin lymphoma.. *American Journal of Translational Research (discontinued)*, **2021**, 13, 12206-12216 3
- 1 A retrospective study on the clinicopathological and molecular features of 22 cases of natural killer/T-cell lymphoma in children and adolescents.. *Scientific Reports*, **2022**, 12, 7118 4.9